Blagosklonny M V, Toretsky J, Bohen S, Neckers L
Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8379-83. doi: 10.1073/pnas.93.16.8379.
The p53 mutant, 143ala, was translated in vitro in either rabbit reticulocyte lysate (RRL) or wheat germ extract (WGE). In RRL, p53-143ala protein of both mutant and wild-type conformation, as detected immunologically with conformation-specific antibodies, was translated. The chaperone protein HSP90, present in RRL, was found to coprecipitate only with the mutated conformation of p53. Geldanamycin, shown previously to bind to HSP90 and destabilize its association with other proteins, decreased the amount of immunologically detectable mutated p53 and increased the amount of detectable wild-type protein, without affecting the total translation of p53. When translated in WGE, known to contain functionally deficient HSP90, p53-143ala produced p53 protein, which was not recognized by a mutated conformation-specific antibody. In contrast, the synthesis of conformationally detectable wild-type p53 in this system was not compromised. Reconstitution of HSP90 function in WGE permitted synthesis of conformationally detectable mutated p53, and this was abrogated by geldanamycin. Finally, when p53-143ala was stably tansfected into yeast engineered to be defective for HSP90 function, conformational recognition of mutated p53 was impaired. When stable transfectants of p53-143ala were prepared in yeast expressing wild-type HSP90, conformational recognition of mutated p53 was antagonized by macbecin I, a geldanamycin analog also known to bind HSP90. Taken together, these data demonstrate a role for HSP90 in the achievement and/or stabilization of the mutated conformation of p53-143ala. Furthermore, we show that the mutated conformation of p53 can be pharmacologically antagonized by drugs targeting HSP90.
p53突变体143ala在兔网织红细胞裂解物(RRL)或麦胚提取物(WGE)中进行体外翻译。在RRL中,用构象特异性抗体免疫检测发现,突变型和野生型构象的p53 - 143ala蛋白均被翻译出来。发现RRL中存在的伴侣蛋白HSP90仅与p53的突变构象共沉淀。之前已证明,格尔德霉素可与HSP90结合并破坏其与其他蛋白质的结合,它减少了免疫可检测到的突变型p53的量,增加了可检测到的野生型蛋白的量,而不影响p53的总翻译量。当在已知含有功能缺陷型HSP90的WGE中翻译时,p53 - 143ala产生的p53蛋白不能被突变构象特异性抗体识别。相反,该系统中构象可检测的野生型p53的合成未受影响。在WGE中重建HSP90功能可允许合成构象可检测的突变型p53,而这被格尔德霉素所消除。最后,当将p53 - 143ala稳定转染到经基因工程改造而HSP90功能缺陷的酵母中时,突变型p53的构象识别受损。当在表达野生型HSP90的酵母中制备p53 - 143ala的稳定转染子时,突变型p53的构象识别被马贝西霉素I拮抗,马贝西霉素I是一种同样已知可与HSP90结合的格尔德霉素类似物。综上所述,这些数据证明了HSP90在p53 - 143ala突变构象形成和/或稳定过程中的作用。此外,我们表明,靶向HSP90的药物可在药理学上拮抗p53的突变构象。